Live Breaking News & Updates on Jamesk Mccloskey

Stay updated with breaking news from Jamesk mccloskey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Concluding Thoughts on Ph+ ALL Treatment

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease. ....

United States , Jamesk Mccloskey , Jonathan Abbas , Ryan Haumschild , Vivian Tambe Ebot , Elias Jabbour , Peer Exchange , Vivian Tambe Ebot Tar , Minimal Residual Disease , Tyrosine Kinase Inhibitor , Standard Of Care ,

The Future of Ph+ ALL Treatments

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease. ....

United States , Jamesk Mccloskey , Jonathan Abbas , Ryan Haumschild , Vivian Tambe Ebot , Elias Jabbour , Peer Exchange , Vivian Tambe Ebot Tar , Minimal Residual Disease , Tyrosine Kinase Inhibitor , Standard Of Care ,

CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra. ....

Gloria Leslie , Jamesk Mccloskey , Lori Leslie , John Theurer Cancer Center , Peer Exchange , Research Programs , Hackensack University Medical Center , Hackensack University Medical , Associate Professor , Indolent Lymphoma ,

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5. ....

Lori Leslie , Jamesk Mccloskey , Gloria Leslie , Peer Exchange , Research Programs , John Theurer Cancer Center , Hackensack University Medical Center , Hackensack University Medical , Associate Professor , Indolent Lymphoma , Mash 2023 , Zuma 7 , Axi Cel , Largeb Cell Lymphoma , Older Population , Cart Cell Therapy , Car T , Overall Survival , Indolent Lymphomas , Follicular Lymphoma , Marginal Zone Lymphoma , Relapsed Refractory Follicular Lymphoma ,

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy. ....

Lori Leslie , Jamesk Mccloskey , Gloria Leslie , Hackensack University Medical Center , John Theurer Cancer Center , Research Programs , Peer Exchange , Hackensack University Medical , Associate Professor , Indolent Lymphoma , While Bruton , Mash 2023 , Sympatico Study , Sympatico Trial , Mantle Cell Lymphoma , Btk Inhibitors , Combination Therapy ,